熱門資訊> 正文

Travere Therapeutics将就肾脏疾病治疗提交SNDA

2025-02-11 20:51

Travere Therapeutics (NASDAQ:TVTX) completed its Type C meeting with the U.S. Food and Drug Administration and plans to submit a supplemental New Drug Application seeking traditional approval of FILSPARI for focal segmental glomerulosclerosis, a rare kidney disorder.
The sNDA will be based on existing data from the Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI and is expected to be submitted around the end of the first quarter of 2025.
Source: Press Release

More on Travere Therapeutics

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue
Vertex leads J.P. Morgan's top biotech picks list for 2025
Seeking Alpha’s Quant Rating on Travere Therapeutics
Historical earnings data for Travere Therapeutics
Financial information for Travere Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。